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Capsid protein VP1 epitopes
a b s t r a c t
Global surveillance for norovirus identiﬁed in 2012 the emergence of a novel pandemic GII.4 variant, termed
Sydney 2012. In Italy, the novel pandemic variant was identiﬁed as early as November 2011 but became
predominant only in the winter season 2012–2013. Upon sequencing and comparison with strains of global
origin, the early Sydney 2012 strains were found to differ from those spreading in 2012–2013 in the capsid
(ORF2) putative epitopes B, C and D, segregating into a distinct phylogenetic clade. At least three residues
(333, 340 and 393, in epitopes B, C and D, respectively) of the VP1 varied among Sydney 2012 strains of
different clades. These ﬁndings suggest that the spread of the pandemic variant in Italy during the winter
season 2012–2013 was due to the introduction of strains distinct from those circulating at low frequency in
the former winter season and that similar strains were also circulating elsewhere worldwide.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Noroviruses (NoVs) are considered as a major cause of acute
gastroenteritis in both children and adults, being responsible for
sporadic cases and outbreaks of gastroenteritis in various epidemio-
logical settings (Green, 2007). NoVs are small round non-enveloped
viruses with a 7.5 kb single stranded positive-sense RNA that contains
three open reading frames (ORFs). ORF1 encodes the non-structural
proteins while ORF2 and ORF3 encode the major and minor capsid
proteins, respectively (Green, 2007).
NoV can be classiﬁed genetically into at least six genogroups, GI to
GVI (Green, 2007; Martella et al., 2009). Although more than 30
genotypes within genogroup GI, GII and GIV may infect humans
(Kroneman et al., 2013) a single genotype, GII.4, has been associated
with the vast majority of NoV-related outbreaks and sporadic cases of
gastroenteritis worldwide (Bok et al., 2009). GII.4 NoV strains con-
tinuously undergo a process of genetic/antigenic diversiﬁcation and
periodically generate novel strains via accumulation of punctate
mutations or recombination. New GII.4 variants emerge every 2–3
years (Eden et al., 2013; Siebenga et al., 2007). Sequence comparison,
structural analysis and characterization of the antigenic and biological
properties of NoV capsid protein using virus-like particles (VLPs) have
revealed that the surface-exposed sub-domain P2 (residues 279 to
405) interacts with potential neutralizing antibodies and with NoV
carbohydrate-binding ligands (Allen et al., 2008; Bok et al., 2009; Bull
et al., 2010; de Rougemont et al., 2011; Lindesmith et al., 2008;
Shanker et al., 2011; Siebenga et al., 2007) and that changes in highly
variable sites (epitopes A to E) within the P2 sub-domain of GII.4 NoVs
correlate with the emergence of new epidemic strains (Lindesmith
et al., 2012, 2013).
Increased incidence of NoV-related outbreaks and or illness in
various countries in the late 2012 has been related to the
emergence of a novel GII.4 variant, Sydney 2012. This variant
was ﬁrst identiﬁed in March 2012 in Australia (van Beek et al.,
2013) and displayed a recombinant origin. A signature of the
variant was a GII.Pe ORF1, in association with GII.4 Apeldoorn
2008-like ORF2-ORF3 genes (Eden et al., 2013). This novel variant
in the capsid gene has a common ancestor with the NoV GII.4
variants Apeldoorn 2008 and New Orleans 2009, although phylo-
genetically distinct, and several amino acid changes are seen in the
main epitope on the P2 sub-domain (van Beek et al., 2013).
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
0042-6822/$ - see front matter & 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.virol.2013.12.007
n Corresponding author. Tel.: þ39 91 6553 6663; fax: þ39 91 655 3676.
E-mail address: giovanni.giammanco@unipa.it (G.M. Giammanco).
Virology 450-451 (2014) 355–358
The Italian Study Group for Enteric Viruses (ISGEV; http://isgev.net)
monitors the epidemiology of enteric viruses in children through
hospital-based surveillance (De Grazia et al., 2013; Giammanco et al.,
2012; Martella et al., 2013; Medici et al., 2012). Monitoring and
characterization of NoVs is achieved by a multi-target analysis of
NoV genome (Kroneman et al., 2011) and consultation of the Nor-
ovirus Typing Tool database (http://www.rivm.nl/mpf/norovirus/
typingtool). Surveillance for NoV in Italy revealed the onset of the
novel pandemic variant GII.4 Sydney 2012 as early as November 2011
(Giammanco et al., 2013), and provided us with some of the earliest
strains of the variant GII.4 Sydney 2012. These early strains originated
from four sporadic cases occurring between November 2011 and
January 2012, and a small outbreak in February 2012. However, the
novel variant subsequently disappeared until the winter season 2012–
2013, when it started circulating at a greater frequency (Giammanco
et al., 2013). Intriguingly, our ﬁndings noted analogous observation
reported from Denmark (Fonageret al., 2013) and Canada (Hasing
et al., 2013), suggesting that a period of adaptation was required for
the novel variant before spreading worldwide. Analysis of early strains
of this variant could be useful to understand if mutations occurred in
adaptive sites or antigenic epitopes of the major capsid protein. In this
study, the sequence of the GII.4 Sydney 2012 NoV strains identiﬁed in
the 2011–2012 and in the 2012–2013 winter seasons in Italy was
determined and compared with cognate sequences available in the
databases.
Results and discussion
Epitopes A to E have been predicted based on sequence
comparison and structural analysis of the P2 subdomain of GII.4
NoVs. These epitopes include mainly surface-exposed, highly
variable sites surrounding the histoblood group antigen (HBGA)
pocket (Lindesmith et al., 2012). However, other residues adjacent
to these putative epitopes might alter NoV strain binding afﬁnity
and speciﬁcity to HBGAs as well as antibody binding and blockade,
either alone or in a coordinated manner. The GII.4 variant Sydney
2012 has been shown to have accumulated several changes in
putative epitopes on the P2 sub-domain with respect to the former
GII.4 variants Den Haag 2006b and New Orleans 2009 (van Beek
et al., 2013) (Table 1). Using monoclonal antibodies and VLPs in
blockade assays, changes in blockade epitopes A and D of the GII.4
variant Sydney 2012 have suggested an appreciable antigenic
variation from previous GII.4 variants (Debbink et al., 2013).
By comparing the early strains of the GII.4 variant Sydney 2012,
PA363/2011/ITA and PA48/2012/ITA, with cognate sequences available
in the databases, at least two clades and a potential ancestor could be
identiﬁed in the Bayesian phylogenetic reconstruction (Fig. 1). A
Canadian strain, AlbertaEi337/2011/CAN, identiﬁed in September
2011 (Hasing et al., 2013) was basal to all the other GII.4 Sydney
2012 strains. The strains PA363/2011/ITA and PA48/2012/ITA formed a
minor clade (2012e) along with NoVs identiﬁed in Australia and
Taiwan (May 2012) and Denmark (December 2012), while strain
PA703/2012/ITA, representative of the 2012–2013 winter season,
segregated into a major clade (2012m) that included the prototype
strain Sydney/NSW0514/2012/AUS (2012p) and strains detectedworld-
wide throughout 2012, distributed in several sub-clusters.
While most residues in antigenic epitopes within the capsid gene
(ORF2) appeared rather conserved across all the GII.4 Sydney 2012
NoV strains, polymorphisms were observed at residues 297 (Arg/His)
and 372 (Asp/Asn) in epitope A and residue 393 (Gly/Ser) in epitope D
(Table 1). Interestingly, all the 2012e minor clade strains showed a
distinctive residue, Met-333, in the predicted epitope B. Ser-393 was
present in the majority of the 2012e strains (including the two Italian
sequences) but it was also displayed by several strains in the clade
2012m. The change 393 Ser to Gly in epitope D has been shown to alter
the blockade phenotype in GII.4 NoVs (Debbink et al., 2013). The
ancestral strain AlbertaEi337/2011/CAN was highly similar to the
reference strain Sydney/NSW0514/2012/AUS in all the epitopes, but
in epitope C for the substitution 340-Thr to Ala. This residue was also
Ala in some strains of the 2012e clade but it was Thr in all the other
Sydney 2012 NoVs. Notably, the early Sydney 2012 strains already
showed the key substitutions in epitope A, at residues 294 and 368,
which are believed to mark the evolution of GII.4 viruses from New
Orleans 2009 to Sydney 2012 (Debbink et al., 2013).
Altogether, our ﬁndings indicate that the Sydney 2012e GII.4 NoV
strains detected in Italy in the 2011–2012 winter season were
phylogenetically different from the strains spreading in the 2012–
2013 winter season. Upon phylogenetic analysis and sequence
comparison with NoV strains of global origin available in the
databases, it was clear that the ﬁndings observed during the NoV
surveillance in Italy were not a local epidemiological pattern but
they rather appeared to reﬂect the global circulation of two distinct
clades (herewith deﬁned 2012e and 2012m) of the pandemic variant
Sydney 2012. The two clades apparently co-circulated during 2012,
although, based on the number of accessions released in the
databases (4 vs 29), the 2012e clade was apparently less successful
epidemiologically than the 2012m clade, at least in areas where
surveillance is reported from. While residue 393 in epitope D was
either Gly or Ser in both clades, Met at position 333 in epitope B
was a hallmark of the 2012e clade. Evolutionary analysis of large
data sets of GII.4 viruses has revealed that residue 333 is under
Table 1
Residues in the epitopes A to E of the variant GII.4 Sydney 2012. A consensus was elaborated using 35 full-length or nearly full-length ORF2 sequences, 29 for clade 2012m
and six for 2012e. Small letter indicate that the polymorphism is less frequent or sporadic. Abbreviations: 2012p, prototype strain Sydney/NSW0514/2012/AUS (JX459908);
2012m, major clade; 2012e, minor early clade; 2012a, ancestral strain AlbertaEI337/2011/CAN. The three residues (333, 340 and 393) signiﬁcantly changing among the clades
are evidenced in light gray.
GII4 Variant Epitopes
A B C D E
294 296 297 298 368 372 333 382 340 376 393 394 395 407 412 413
US95/96 1996 A S H D T N M K E Q G - N N T G
Farmington Hills 2002 A T H N N N M K G E N G A S T G
Hunter 2004 A A Q N S S V R R E S T T D D S
Minerva/Den Haag 2006b A S R N S E V K G E S T T S N V
Apeldoorn 2007 T S R N A D V K T D D T A S N N
New Orleans 2009 P S R N A D V K T E S T T S N I
Sydney 2012a T S R N E D V K A E S T T S N T
Sydney 2012e T S R N E D M K T/a E S/g T T S N T
Sydney 2012p T S R N E D V K T E S T T S N T
Sydney 2012m T S R/h N E D/n V K T E G/S T T S N/d T
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positive directional selection (Siebenga et al., 2010). Epitope B is
formed by two variable residues at position 333 and 382, that are
buried in the dimer interface between two chains of the capsid
protein and are likely to inﬂuence exposure of residues located on
more surface-exposed epitopes (Lindesmith et al., 2012). Interest-
ingly, residue 333 was Val in the ancestral Canadian strain Alber-
taEi337/2011/CAN. This strain, although phylogenetically ancestral,
already possess the same epitope asset as the strains in the major
clade 2012m of the Sydney 2012 variant, with the only exception of
the change 340-Thr to Ala in epitope C. Residue 340 is also Ala in
some strains within the minor phylogenetic clade 2012e. The
putative conformational epitope C is made up of two residues
(340 and 376) and it is located on the surface and lateral edge of the
capsid, directly proximal to the HBGA pocket (Lindesmith et al.,
2012). When comparing chronologic sets of GII.4 variants, residue
340 stands out among the variable sites (Siebenga et al., 2007) as it
changes consistently across the GII.4 variants (Glu1996-
Gly2002-Arg2004-Gly2006b-Thr2009-Ala/Thr2012).
Accordingly, at least three residues (333, 340 and 393) mapped to
three different VP1 putative epitopes, B, C and D, appeared to vary
between the phylogenetic clades of the Sydney 2012 variant (Table 1).
Conclusions
In conclusion, there is evidence that different capsid gene sub-
lineages of the novel NoV variant GII.4 Sydney 2012 have been co-
circulating globally since the late 2011. Mutations in adaptive
residues at positions 333, 340 and 393 of the viral capsid protein
were identiﬁed that likely played a role in the evolution/adapta-
tion of the novel pandemic GII.4 variant. However, it may not be
ruled out that other mechanisms, yet not identiﬁed, were also
involved. A more in-depth understanding of the evolutionary
pathway followed by GII.4 NoVs is important to predict the
emergence of new pandemic strains and optimize vaccine design.
Material and methods
The GII.4 variant Sydney 2012 was ﬁrst identiﬁed in Italy in
November 2011. An additional three sporadic cases of gastro-
enteritis and a small outbreak by this NoV variant occurred throughout
February 2012. On the basis of alignment and phylogenetic analysis on
short diagnostic regions A and C of NoV genome (Kroneman et al.,
Fig. 1. Phylogenetic analysis on GII.4 Sydney 2012 NoV strains. The bayesian tree was generated using the nearly full-length ORF2 nucleotide sequence of strains of the GII.4 NoV
variant Sydney 2012. Numbers on the tree branches indicate the posterior probability values. The two clades, 2012e and 2012m, are evidenced. The Italian strains are boxed.
Abbreviations: 2012m, major clade; 2012e, minor early clade; 2012a, ancestral strain AlbertaEI337/2011/CAN; 2012p, prototype strain Sydney/NSW0514/2012/AUS (JX459908).
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2011), two strains were selected among the ﬁve strains detected in
Palermo, Sicily, in the 2011–2012 winter season as the earliest
representatives of GII.4 Sydney variant. Strain PA363/2011/ITA was
detected in November 2011, while strain PA48/2012/ITA was detected
in January 2012 thus encompassing the beginning and the end of the
epidemic season. A strain of the 2012–2013 winter epidemic, PA703/
2012/ITA, identiﬁed in December 2012, was also selected on the basis
of previous alignment and phylogenetic analysis of regions A and C
(Kroneman et al., 2011) as representative of the strains circulating in
the season (data not presented). A 30 RACE-PCR protocol (Wang et al.,
2005) was used to generate a 3.2 kb amplicon encompassing the 30
end of ORF1, the full-length ORF2 and ORF3, the 30 untranslated region
(UTR) through the poly-A tail. Brieﬂy, cDNA was synthesized by
SuperScript III First-Strand cDNA synthesis kit (Invitrogen Ltd, Paisley,
UK) with primer VN3T20 (50-GAGTGACCGCGGCCGCT20-30). PCR was
then performed with TaKaRa La Taq polymerase (TaKaRa Bio Europe
SAS, Saint-Germain en-Laye, France) with forward primer JV12Y
(Vennema et al., 2002) and the reverse primer VN3T20 (Wang et al.,
2005). The amplicons were puriﬁed and cloned using TOPOXL Cloning
Kit (Invitrogen Ltd, Paisley, UK). Additional primers were designed to
determine the complete 3.2-kb sequence by an overlapping strategy.
Sequence editing and multiple codon-based (translation) alignments
were performed with Geneious software v6.2. The sequences of the
NoV strains are available in GenBank under accession numbers
KF668567, KF668568, KF668569. Phylogenetic analysis and sequence
comparison were performed on the full-length OFR2 sequences
produced in this study and on a set of 34 complete ORF2 sequences
of GII.4 Sydney 2012 NoVs retrieved from the databases. Consultation
of the databases was terminated on 2 August 2013. Several algorithms
were used to infer phylogenetic trees using MEGA 5.0 software
(Tamura et al., 2011) and MrBayes version 3.2.1 (Huelsenbeck and
Ronquist, 2001). The appropriate substitution model settings were
derived using jModelTest (Posada, 2009).
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